Trump wants Big Pharma to split MMR vaccine; Big Pharma thinks it's idiotic

A recent executive directive issued by President Donald Trump aiming to fundamentally alter childhood immunization guidelines has sparked intense pushback from medical professionals and the pharmaceutical industry alike.

The order, which advocates for reducing the overall number of shots given to children, proposes splitting the combined measles, mumps, and rubella (MMR) vaccine into three separate injections. Medical advocacy groups, including the American Academy of Pediatrics, have condemned the directive as unsafe and unscientific, arguing that it contradicts established healthcare protocols and threatens public health. Furthermore, the pharmaceutical sector has raised significant logistical concerns, highlighting that separate vaccines for these three diseases are currently unavailable in the United States, meaning companies would have to create them from scratch.

Major pharmaceutical corporations and their primary trade association, PhRMA, argue that dismantling the combined MMR vaccine lacks any clinical justification and ignores decades of rigorous scientific evidence supporting its safety and efficacy. Industry representatives pointed out that implementing this mandate would require massive, unnecessary investments to research, manufacture, and test entirely new, individual vaccines without any proven medical benefit. Critics also emphasize that dividing the doses would increase the total physical injection burden on children from two shots to six, ultimately undermining the administration's stated goal of minimizing the quantity of vaccinations. This coordinated resistance highlights a rare public alignment between commercial drug manufacturers and scientific advocacy groups against executive health directives.